Evidence map›Paper›PMID 9382886›Full record

ArticleThe Journal of experimental medicine1997

C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.

M Trudel, J Lanoix, L Barisoni, M J Blouin, M Desforges, C L'Italien, V D'Agati

Open access · greenAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. Article
  3. ModelingMolecular therapy. Methods & clinical development · 2023
    Article
  4. Article
  5. Empowering Melatonin Therapeutics withDiseases (Basel, Switzerland) · 2021
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. MYC and the control of apoptosis.Cold Spring Harbor perspectives in medicine · 2014
    Review
  16. Review
  17. Polycystins and cellular Ca2+ signaling.Cellular and molecular life sciences : CMLS · 2013
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

M TrudelInstitut de Recherches Cliniques de Montréal, Faculté de Médecine de l'Université de Montréal, Montréal, Québec, Canada H2W 1R7.
J Lanoix
L Barisoni
M J Blouin
M Desforges
C L'Italien
V D'Agati
Montreal Clinical Research Institute · CAUniversité de Montréal · CAColumbia University · US

Funding

MOLECULAR GENETIC ANALYSIS OF PKD IN TRANSGENIC MICER01DK044864 · NIDDK · UNIVERSITY OF MONTREAL · PI TRUDEL, MARIE · 1992 to 1994
–
NIDDK NIH HHS DK44864
6 · The paper itself

Abstract

The SBM mouse is a unique transgenic model of polycystic kidney disease (PKD) induced by the dysregulated expression of c-myc in renal tissue. In situ hybridization analysis demonstrated intense signal for the c-myc transgene overlying tubular cystic epithelium in SBM mice. Renal proliferation index in SBM kidneys was 10-fold increased over nontransgenic controls correlating with the presence of epithelial hyperplasia. The specificity of c-myc for the proliferative potential of epithelial cells was demonstrated by substitution of c-myc with the proto-oncogene c-fos or the transforming growth factor (TGF)-alpha within the same construct. No renal abnormalities were detected in 13 transgenic lines established, indicating that the PKD phenotype is dependent on functions specific to c-myc. We also investigated another well characterized function of c-myc, the regulation of apoptosis through pathways involving p53 and members of the bcl-2 family, which induce and inhibit apoptosis, respectively. The SBM kidney tissues, which overexpress c-myc, displayed a markedly elevated (10-100-fold) apoptotic index. However, no significant difference in bcl-2, bax, or p53 expression was observed in SBM kidney compared with controls. Direct proof that the heightened renal cellular apoptosis in PKD is not occurring through p53 was obtained by successive matings between SBM and p53(-/-) mice. All SBM offspring, irrespective of their p53 genotype, developed PKD with increased renal epithelial apoptotic index. In addition, overexpression of both bcl-2 and c-myc in double transgenic mice (SBB+/SBM+) also produced a similar PKD phenotype with a high apoptotic rate, showing that c-myc can bypass bcl-2 in vivo. Thus, the in vivo c-myc apoptotic pathway in SBM mice occurs through a p53- and bcl-2-independent mechanism. We conclude that the pathogenesis of PKD is c-myc specific and involves a critical imbalance between the opposing processes of cell proliferation and apoptosis.

Indexed as

AnimalsApoptosisCell DivisionCrosses, GeneticDisease Models, AnimalEpithelial CellsGene ExpressionGenes, mycGenes, p53Genes, SyntheticHyperplasiaKidney TubulesMiceMice, KnockoutMice, TransgenicOrgan SpecificityProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycRecombinant Fusion ProteinsTumor Suppressor Protein p53

Identifiers

PMID9382886
PMCPMC2199149
OpenAlexW2070702585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.